Biopsy DNA clues could spare esophageal cancer patients from futile chemo

NCT ID NCT06490003

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study investigates whether DNA methylation patterns in tumor biopsy samples can predict how well esophageal cancer patients will respond to chemotherapy. Researchers aim to develop a model that identifies patients unlikely to benefit from standard chemo drugs like Fluorouracil and Cisplatin. The study enrolls 150 adults with esophageal squamous cell carcinoma who are receiving their first round of chemotherapy. If the model works, it could help personalize treatment and avoid ineffective therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Fluoro Uracil (Cisplatin)
What this could lead to
If successful, this could help doctors quickly identify which esophageal cancer patients won't benefit from standard chemotherapy, allowing them to explore alternative treatments sooner.
What could go wrong
This is an early-stage model development study with 150 participants. The DNA methylation prediction method may not prove accurate enough for clinical use, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY EFFECT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Yamanashi Universiy

    RECRUITING

    Chūō, Yamanashi, 4093898, Japan

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.